Fibrosis is a pathological condition characterized by the excessive deposition of extracellular matrix due to the imbalance between injury and repair. It can affect multiple organs, including the heart, lungs, liver, kidneys, and pancreas. The progression of fibrosis is usually slow and difficult to reverse, and it can severely impair organ functions. In industrialized countries, deaths caused by fibrosis account for up to 45%, resulting in a tremendous disease burden. Thus, there is an urgent need for drugs that can reverse or delay the progression of fibrosis. In recent years, remarkable progress has been made in the research on the pathogenesis of fibrosis in different organs, and relevant drugs targeting fibrosis are also under active development. This article briefly summarizes the drugs currently marketed and drugs at the clinical trial stage for treating fibrosis.